Skip to Navigation
Skip to Main Content
Skip to Related Content
to view your mail
Yahoo Finance Plus
U.S. Markets closed
Protagenic Therapeutics, Inc. (PTIX)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
At close: 4:00PM EDT
127 reactions on $PTIX conversation
Sign in to post a message.
Protogenics Therapeatics investor deck pretty much checks out after reading every published article on TCAP , a neuropeptide that modulates the stress response in the brain.
One thing in the DD that sticks out from multiple published articles on teneurin ,the full length neuropeptide peptide TCAP is associated with ( Teneurin C associated peptide TCAP)
that’s concentrated in synapses and
plays an essential role in axonal pathfinding.
TCAP also has an interesting role in synapse and dendrite formation.( see pictures on page 8 in investor deck)
The first 3 cohort groups recruited will have PTSD , major depression disorder, general anxiety disorder will “ALL”have elevated cortisol levels so they know their condition is associated with hypothalamic pituitary adrenal axis hyper-activation.
PTIX’s has worldwide exclusive rights to commercialize synthetic TCAP with ph 1/2a trials starting end of Q4 2021 after 3 month delay to refile NDA after FDA asked for all individual dosing levels be pre supplied to trial sights instead of clinics formulating dose levels.
Exploring efficacy in additional stress related neuropsychiatric and mood disorders beyond initially targeted indications also in
Alzheimer’s and Parkinson’s disease are planned after safety trial data I imagine seeing the operation WARP speed the FDA is talking about adopting to address the growing Alzheimer’s challenges.
They have done non human primate pre clinical work so I’m thinking any liver toxicity etc. analysis has given them confidence ph1 human safety trials risks have been lowered.
PTIX CEO Garo H. Armen, Ph.D. who is also CEO of Agenus inc. $1.2 billion MC.
and they’re anything but amateur.
Looks like the FDA delay is just minor nitpicking compared to the majority of reasons FDA requests changes in IND apps.
Not much of a history on PTIX to go by yet but Agnus has a large therapeutic pipeline with first class management and a couple of their exec’s are also involved with Protogenics.
Looking forward to Christmas as these guys finally get this therapeutic into clinics.
I don’t know how I ever traded without using (
)! I look forward to their daily emails each morning that list pre-market movers based on thoroughly researched stock market and world news. I highly recommend anyone who invests in the stock market!
what's happening ah
Thanks for the 10% gain in 15 minutes today..
What a country America!!!!
It was tempted to buy had $2.75. but I waited and it ended up getting it at $2.24 in aftermarket. This is going to $3 tomorrow maybe even more
Oh nice 2.09 I doubled down
For those who may not be aware, this company's primary candidate is PT00114, a teneurin C-terminal associated peptide (TCAP), which is a naturally occurring peptide responsible for the regulation of stress response in the brain. Stress is a primary driver and/or byproduct of depression, addiction, and PTSD, resulting in elevated levels of cortisol. PT00114 has been shown to reduce levels of cortisol by restoring/repairing disordered nerve function with a resultant increased ability for glucose uptake and a reduction in the production of cortisol. The results in animal testing have been very positive for efficacy as measured by a reduction of cortisol. As opposed to leading candidates currently on the market, PT00114 does not produuce sedation - it simply delivers an increased amount of what is a naturally occuring compound that is the brain's mechanism for dealing with stress. Also, the effects are felt within hours, rather than days or weeks as is the case with common anti-depressants already on the market. I may be the last one to have learned these details, but on the off chance, I wanted to share what I learned from watching a recent presentation made by Dr. Garo Armen, Executive Chairman.
While we should be getting news soon about the trial to be conducted by Dr. Maurizio Fava, Psychiatrist-in-Chief at Massachusetts General Hospital (MGH).
I have been holding the warrants for a while and expect to hold them quite a bit longer - on the most aggressive timeline, FDA approval won't come until 2022. But I will be adding to my position along the way and I am very excited to hear the results of the first trial with human subjects.
Easy short huh?
Sir Robert the Stalwart
Not a single post on this message board about any news that triggered the massive rise in volume yesterday. The public offering news was 12 day go, so that was not what triggered the action yesterday. There must be some other news. What is it?
This stock has flown under the radar until today. Stock offering at $4.15 per share and warrants exercisable at $4.98 per share. The stock trades at only $2.45 in after hours trading as we speak. Just loaded up as this will climb very fast to the $4.00+ level.
All you need to know is that Dr. Maurizio Fava is the principal clinician in the trials. He is a world renown leader in depression. No way he puts his name on this. He must have been very impressed with initial indications of PT00114
The company's, Q2 earnings came out yesterday.
so what's with the after-hours on Yahoo it's saying it's up a buck something but the price doesn't say that
a very undervalued stock
⭐ This is a very Bullish Chart, traders! 💰💵📈
Power hour will hopfully bring us to 4.00 to close the day!
Did anyone read the publication link below? The Phase 1/2 Trial Cohort will start in early June 2021. So, are we suppose to get some kind of this news soon?
Trading way bellow the offering price of $4.98. Someone willing to pay that price knowing the upside potential. Adding on the weakness.
Saved by grace
Trust in JESUS
FedEx just painted a disturbing picture of the job market
The municipal bond market is 'overvalued' : Black Rock Municipal Bonds Group Head
Yahoo Finance Video
Bill Gates is hanging on to these stocks for steady income — you can too
Advertise with us
© 2021 Verizon Media. All rights reserved.
About Our Ads
Discover new investment ideas by accessing unbiased, in-depth investment research